Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations

BACKGROUND: CDKN2A and TP53 mutations are recurrent events in melanoma, occurring in 13.3% and 15.1% of cases respectively and are associated with poorer outcomes. It is unclear what effect CDKN2A and TP53 mutations have on the clinical outcomes of patients treated with checkpoint inhibitors. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: DeLeon, Thomas T., Almquist, Daniel R., Kipp, Benjamin R., Langlais, Blake T., Mangold, Aaron, Winters, Jennifer L., Kosiorek, Heidi E., Joseph, Richard W., Dronca, Roxana S., Block, Matthew S., McWilliams, Robert R., Kottschade, Lisa A., Rumilla, Kandelaria M., Voss, Jesse S., Seetharam, Mahesh, Sekulic, Aleksandar, Markovic, Svetomir N., Bryce, Alan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083309/
https://www.ncbi.nlm.nih.gov/pubmed/32196516
http://dx.doi.org/10.1371/journal.pone.0230306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083309/
https://www.ncbi.nlm.nih.gov/pubmed/32196516
http://dx.doi.org/10.1371/journal.pone.0230306

Ejemplares similares